<DOC>
	<DOCNO>NCT02343744</DOCNO>
	<brief_summary>The purpose study examine descriptively efficacy CNTO 1959 participant generalize pustular psoriasis ( GPP ) erythrodermic psoriasis ( EP ) .</brief_summary>
	<brief_title>An Efficacy Safety Study CNTO1959 ( Guselkumab ) Treatment Participants With Generalized Pustular Psoriasis Erythrodermic Psoriasis</brief_title>
	<detailed_description>This phase 3 , multicenter ( one hospital medical school team work medical research study ) , open-label study evaluate efficacy safety CNTO1959 ( Guselkumab ) treatment participant GPP EP . Participants receive 50 milligram ( mg ) guselkumab subcutaneously Weeks 0 , 4 12 . At Week 16 Week 52 participant define `` Very much improve '' `` Much improve '' Clinical Global Impression ( CGI ) continue receive guselkumab 50 mg every 8 week Week 20 study end ( Week 52 ) . At visit time Week 20 , participant define `` No change '' `` Worsened '' receive guselkumab 100 mg continue 100 mg every 8 week dose Week 52 . Participants `` Minimally improve '' also receive guselkumab 100 mg investigator considers necessary . Participants primarily assess treatment success . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis generalize pustular psoriasis ( GPP ) erythrodermic psoriasis ( EP ) screening . A diagnosis GPP must classify basis criterion diagnosis GPP Japanese Dermatological Association ( JDA ) Have history plaquetype psoriasis subject diagnosis EP Have involve body surface area ( BSA ) lesion great equal ( &gt; = ) 80 percent ( % ) baseline subject diagnosis EP . Be candidate phototherapy systemic treatment psoriasis ( either na√Øve history previous treatment ) Before first administration study drug , woman must either childbearing potential childbearing potential practicing highly effective method birth control , consistent local regulation regard use birth control method subject participate clinical study Has total score JDA severity index GPP &gt; =14 baseline subject diagnosis GPP Has differential diagnosis erythroderma ( exmaple ( eg ) , erythroderma cause lymphoma drug eruption ) EP . Has refuse hospitalization though investigator need hospitalization Has body mass index ( BMI ) less ( &lt; ) 18 kilogram per square meter ( kg/m^2 ) meet follow modify criterion cachexia . Has BMI &lt; 20 kg/m^2 lose 5 % body weight previous month , 4 follow present : ) decrease muscle strength b ) fatigue reduce physical activity c ) anorexia ) low muscle mass e ) CRP great ( &gt; ) 7 mg/L 6 ) hemoglobin ( Hb ) &lt; 12 gram per deciliter ( g/dL ) f ) serum albumin &lt; 3.0 g/dL Has Common Terminology Criteria Adverse Events ( CTCAE ) Version 4 Grade 2 high heart failure CTCAE v.4 Grade 3 high kidney failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Generalized Pustular Psoriasis</keyword>
	<keyword>Erythrodermic Psoriasis</keyword>
	<keyword>Guselkumab</keyword>
	<keyword>CNTO1959</keyword>
</DOC>